



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



IRAK4 Inhibitor 28

Item No. 40167

CAS Registry No.: 2196204-23-4
Formal Name: N-[*trans*-4-(4-morpholinyl)cyclohexyl]-5-(tetrahydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Synonym: IRAK4-IN-28
MF: C₂₁H₃₁N₅O₂
FW: 385.5
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

IRAK4 inhibitor 28 is supplied as a solid. A stock solution may be made by dissolving the IRAK4 inhibitor 28 in the solvent of choice, which should be purged with an inert gas. IRAK4 inhibitor 28 is soluble in chloroform and DMSO.

Description

IRAK4 inhibitor 28 is an inhibitor of IL-1 receptor-associated kinase 4 (IRAK4; IC₅₀ = 0.005 μM).¹ It is selective for IRAK4 over IRAK1, CDC-like kinase 1 (Clk1), and Clk3 (IC₅₀s = 0.023, 0.05, and >1 μM, respectively) but does inhibit Clk2, Clk4, and haspin (IC₅₀s = 0.005, 0.008, and 0.004 μM, respectively). IRAK4 inhibitor 28 (0.12-3.3 μM) inhibits IκBα phosphorylation in OCI-LY10 diffuse large B cell lymphoma (DLBCL) cells. *In vivo*, IRAK4 inhibitor 28 (12.5 mg/kg) reduces tumor volume in an OCI-LY10 mouse xenograft model.

Reference

1. Scott, J.S., Degorce, S.L., Anjum, R., *et al.* Discovery and optimization of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) for the treatment of mutant MYD88^{L265P} diffuse large B-cell lymphoma. *J. Med. Chem.* **60**(24), 10071-10091 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/13/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM